NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and...
SutroVax Announces $85M Series C Financing led by TPG Growth
SutroVax Announces $85M Series C Financing led by TPG Growth Provides growth capital to advance pneumococcal vaccine to clinic and beyond Preeminent executive vaccinologist, Moncef Slaoui, appointed Board Chairman Strategic alignment established with Lonza Pharma...
American Society of Clinical Oncology (ASCO) 2018 – Poster
A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF STRO-001, AN ANTI-CD74 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES, NCT03424603
Sutro CEO, Bill Newell appointed Chair of the California Life Sciences Association.
https://califesciences.org/california-life-sciences-association-elects-new-board-chair-adds-new-board-member/ California Life Sciences Association Elects New Board Chair, Vice Chair And Adds New Board Member SAN FRANCISCO, SACRAMENTO & SAN DIEGO, Calif., May 30,...
Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs
SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate, STRO-001, targeting CD74, a protein highly expressed in B-cell...
American Association for Cancer Research (AACR) 2018 – STRO-002 Poster
Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR 2018 Poster Final
Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research
- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in...
American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract
Generation and Activity of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Folate receptor alpha (FolRa) is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is highly expressed in serous and epithelial ovarian cancer...
Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract
Preclinical Activity and Safety of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, that is a promising target...